|
Research
Front Name
|
Percentage of corporate affiliations
|
Leading
corporation
|
|
LIQUID CHROMATOGRAPHY/ATMOSPHERIC PRESSURE IONIZATION
MASS SPECTROMETRIC BIOANALYTICAL METHODS
|
48
|
Merck & Company
|
|
TYPE 2 DIABETES; THIAZOLIDINEDIONE MONOTHERAPY
|
39
|
Novartis
|
|
HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR
|
32
|
Boehringer Ingelheim
|
|
EARLY DRUG DISCOVERY; HIGH-RESOLUTION LIQUID
CHROMATOGRAPHY/QUADRUPOLE TIME-OF-FLIGHT MASS
SPECTROMETRY
|
28
|
Waters Corporation
|
|
PROTEIN-LIGAND DOCKING; VIRTUAL SCREENING; FULLY
AUTOMATIC FLEXIBLE MOLECULAR DOCKING
|
25
|
Astex Technology
|
|
NOVEL P38 ALPHA MAP KINASE INHIBITORS USING
FRAGMENT-BASED LEAD GENERATION; FRAGMENT-BASED DRUG
DISCOVERY
|
24
|
Astex Technology
|
|
NOVEL TYROSINE KINASE INHIBITOR TARGETING VASCULAR
ENDOTHELIAL GROWTH FACTOR; SMALL-MOLECULE FLT3 TYROSINE
KINASE INHIBITOR
|
23
|
Sugen, Inc
|
|
MULTI-TARGET-DIRECTED LIGANDS; MAGIC BULLETS;
RATIONALLY DESIGN PROMISCUOUS DRUGS; SYSTEMS-ORIENTED
DRUG DESIGN
|
21
|
Organon
|
|
HISTORICAL LOCAL LYMPH NODE DATA; REACTION MECHANISTIC
APPLICABILITY DOMAIN CLASSIFICATION; SKIN SENSITIZATION
ALTERNATIVE METHODS
|
21
|
GlaxoSmithKline
|
|
NONINFLAMMATORY SYNTHETIC SIRNA; POTENT GENE SILENCING
IN-VIVO; SMALL INTERFERING RNA INHIBITS TUMOR GROWTH
|
21
|
Alnylam Pharmaceuticals
|
